The Latest Analyst Ratings for BioNTech
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 15 analysts have published their opinion on BioNTech (NASDAQ:BNTX) stock, with 7 bullish and 8 indifferent ratings. The company has an average 12-month price target of $163.07, a decrease of 10.37% from the previous average of $181.93.
June 01, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech has received mixed opinions from 15 analysts, with 7 bullish and 8 indifferent ratings. The average 12-month price target is $163.07, down 10.37% from the previous average.
The article provides an overview of analyst ratings for BioNTech over the past 3 months. With a mix of bullish and indifferent ratings, the stock's short-term impact is neutral. The decrease in the average 12-month price target may indicate a slightly less optimistic outlook, but the overall sentiment remains mixed.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100